Polymedco — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Polymedco is a commercial-stage, privately-held diagnostics company with a 40-year history focused on screening and early detection. Its core business revolves around two flagship product lines: the OC-Auto® FIT system for colorectal cancer (CRC) screening and the PATHFAST® Cardiac Biomarker Analyzer for point-of-care cardiac testing. The company leverages robust clinical evidence and programmatic support to drive patient compliance and improve clinical outcomes, positioning itself as a partner to healthcare systems and laboratories. Its strategy is built on delivering user-friendly, high-performance tests backed by extensive data and customer-centric implementation services.

OncologyCardiology

Technology Platform

Focused on automated, user-friendly diagnostic systems for high-throughput and point-of-care settings. Core platforms are the OC-Auto® system for automated fecal immunochemical testing (FIT) for colorectal cancer screening and the PATHFAST® benchtop immunoassay analyzer for quantitative, lab-quality cardiac biomarker testing at the point of care.

Opportunities

The expansion of colorectal cancer screening guidelines to a younger population and global efforts to improve suboptimal screening rates present a sustained growth opportunity for the OC-Auto FIT system.

Furthermore, the recent FDA clearance for the high-sensitivity troponin I assay on the PATHFAST platform allows Polymedco to capitalize on the accelerating clinical adoption of rapid, point-of-care cardiac testing in emergency and acute care settings.

Risk Factors

Polymedco faces intense competition in both its core markets from large, well-capitalized diagnostics corporations and alternative screening technologies.

The company is also subject to regulatory changes and reimbursement pressures from payors, which can impact test adoption and pricing.

Long-term technological disruption, such as blood-based multi-cancer early detection tests, could challenge its colorectal cancer screening business.

Competitive Landscape

In colorectal cancer screening, Polymedco competes with other FIT manufacturers, stool DNA tests (e.g., Exact Sciences' Cologuard), and colonoscopy. In point-of-care cardiac testing, it faces major players like Abbott (i-STAT), Roche (cobas h 232), Siemens Healthineers (Atellica VTLi), and Danaher (Radiometer). Its differentiation relies on product performance, clinical evidence, programmatic support, and a customer-centric partnership model.

More companies in Diagnostics & Precision Medicine →More companies in United States →